Michael L. Vazquez
Pfizer (United States)(US)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Cytokine Signaling Pathways and Interactions, Synthesis and biological activity, Estrogen and related hormone effects, Chemical Synthesis and Analysis
Most-Cited Works
- → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited
- → A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/Glycine/Ion channel receptor macrocomplex(1990)69 cited
- → Synthesis, Crystal Structure, and Activity of Pyrazole-Based Inhibitors of p38 Kinase(2007)64 cited
- → Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor(2010)64 cited
- → Selective inducible microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from an oxicam template(2010)61 cited
- → Inhibitors of HIV-1 Protease Containing the Novel and Potent (R)-(Hydroxyethyl)sulfonamide Isostere(1995)48 cited
- → Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation(2012)48 cited
- → Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study(2018)45 cited
- → Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells(2017)32 cited
- → Benzodipyrazoles: a new class of potent CDK2 inhibitors(2005)29 cited